Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ELANE | P08246 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7416537 | 0.84 | APP (0.50) | APPALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL5372364 | 0.84 | APP (0.50) | APPALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL5375571 | 0.81 | ALDH1A1 (0.48) | ALDH1A1ELANEKDM4EMAPTHTT | |
| SCHEMBL5363855 | 0.77 | ALDH1A1 (0.63) | ALDH1A1ELANEHPGDHSD17B10MAPT | |
| SCHEMBL6494571 | 0.77 | ALDH1A1 (0.63) | ALDH1A1ELANEHPGDHSD17B10MAPT | |
| SCHEMBL5363157 | 0.75 | POLB (0.52) | ALDH1A1ELANEKDM4ETSHRMAPT | |
| SCHEMBL5367817 | 0.73 | FDPS (0.52) | ALDH1A1ELANEMAPTHTT | |
| SCHEMBL12282007 | 0.73 | APP (0.65) | APPALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL9728830 | 0.72 | ADORA3 (0.58) | APPALDH1A1KDM4EHPGDTSHR | |
| SCHEMBL8407071 | 0.72 | ECE1 (0.55) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7279472-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-10-09 | — | — | US | disclosed |
| US-7265132-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-7056915-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-6982272-B2 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2006-01-03 | — | — | US | disclosed |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| US-6756372-B2 | FOR THERAPY OF AUTOIMMUNE DISEASES, ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, CROHN'S DISEASE, ULCERATIVE COLITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, PSORIASIS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-06-29 | — | — | US | disclosed |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | US | disclosed |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
| EP-1218372-B1 | NOVEL HETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2003-07-02 | — | — | EP | disclosed |
| US-6420364-B1 | TREATING AUTOIMMUNE DISEASES,ALZHEIMER'S DISEASE, ATHEROSCLEROSIS, OSTEOPOROSIS, | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1218372-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | Boehringer Ingelheim Pharmaceuticals, Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | EMMANUEL MICHEL JOSE (US) | 2002-05-16 | — | — | US | disclosed |
| WO-2001019816-A1 | NOVEL SPIROHETEROCYCLIC COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032772-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | APP 2114/4885ALDH1A1 2061/4885ELANE 52/4885 |
| US-20020058809-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | APP 2107/4885ALDH1A1 1811/4885ELANE 56/4885 |
| US-20030225270-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | APP 2107/4885ALDH1A1 1811/4885ELANE 56/4885 |
| US-20050032792-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | APP 2265/4885ALDH1A1 1878/4885ELANE 67/4885 |
| US-20030225271-A1 | Compounds useful as reversible inhibitors of cysteine proteases | CTSS, CTSK, CTSB | APP 2107/4885ALDH1A1 1811/4885ELANE 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.